Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

XBIT

XBiotech (XBIT)

XBiotech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XBIT
DateTimeSourceHeadlineSymbolCompany
05/10/202410:27AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
02/07/202411:36AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
02/07/202411:01AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
01/05/20249:48AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XBITXBiotech Inc
01/04/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XBITXBiotech Inc
01/04/20248:00AMGlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
01/04/20248:00AMGlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
11/14/20238:00AMGlobeNewswire Inc.Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisNASDAQ:XBITXBiotech Inc
11/09/20231:41PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
09/26/20238:00AMGlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeNASDAQ:XBITXBiotech Inc
08/30/20238:00AMGlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic CancerNASDAQ:XBITXBiotech Inc
08/11/202310:18AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
08/08/202310:47AMGlobeNewswire Inc.XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialNASDAQ:XBITXBiotech Inc
06/26/20237:48AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
06/26/20237:46AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
06/26/20237:43AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
06/26/20237:40AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
06/23/20232:04PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XBITXBiotech Inc
06/20/20238:20AMEdgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:XBITXBiotech Inc
05/22/20238:00AMGlobeNewswire Inc.FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsNASDAQ:XBITXBiotech Inc
05/17/20238:22AMEdgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:XBITXBiotech Inc
05/17/20238:00AMGlobeNewswire Inc.XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesNASDAQ:XBITXBiotech Inc
05/10/20232:42PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XBITXBiotech Inc
04/28/202311:38AMEdgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:XBITXBiotech Inc
04/28/202311:33AMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XBITXBiotech Inc
02/15/20235:12AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XBITXBiotech Inc
02/10/202311:22AMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
02/10/202311:21AMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
02/10/202311:21AMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
01/12/20239:29AMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
 Showing the most relevant articles for your search:NASDAQ:XBIT